CheckMate 227 Induced Manageable Toxicities With Immunotherapy Combination in NSCLC
Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.
Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab (Opdivo) plus ipilimumab (Yervoy) as treatment of patients with non–small cell lung cancer (NSCLC).
One question that often comes up regarding combining multiple immunotherapies is whether there is a high incidence of autoimmune toxicity and the impact of that is on patients, Ramalingam says. Based on the long-term data from this trial, most salient toxicities occurred within the first 6 months of treatment and were manageable in the majority of patients.
Beyond the 6-month time period, the likelihood of developing any of these toxicities is relatively low, which shows that with supportive care, patients are able to get through the planned 2 years of therapy. This is reassuring to both the patient and physician, says Ramalingam.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
